Head to Head Survey: Ariad Pharmaceuticals (ARIA) & Its Rivals

Ariad Pharmaceuticals (NASDAQ: ARIA) is one of 293 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Ariad Pharmaceuticals to related businesses based on the strength of its dividends, risk, analyst recommendations, institutional ownership, earnings, valuation and profitability.

Institutional & Insider Ownership

87.0% of Ariad Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 8.2% of Ariad Pharmaceuticals shares are owned by company insiders. Comparatively, 17.3% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Ariad Pharmaceuticals and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Ariad Pharmaceuticals N/A N/A N/A
Ariad Pharmaceuticals Competitors $293.65 million $35.70 million 69.96

Ariad Pharmaceuticals’ rivals have higher revenue and earnings than Ariad Pharmaceuticals. Ariad Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings for Ariad Pharmaceuticals and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ariad Pharmaceuticals 0 0 0 0 N/A
Ariad Pharmaceuticals Competitors 1214 3583 12107 251 2.66

As a group, “Bio Therapeutic Drugs” companies have a potential upside of 38.54%.

Profitability

This table compares Ariad Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ariad Pharmaceuticals -60.47% N/A -17.16%
Ariad Pharmaceuticals Competitors -5,585.47% -160.76% -35.81%

Summary

Ariad Pharmaceuticals beats its rivals on 4 of the 7 factors compared.

Ariad Pharmaceuticals Company Profile

ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Receive News & Ratings for Ariad Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ariad Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply